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Abstract
T-cell-based immunotherapy, such as CAR-T cells and bispeciﬁc T-cell engagers (BiTEs), has shown promising clinical
outcomes in many cancers; however, these therapies have signiﬁcant limitations, such as poor pharmacokinetics and the ability
to target only one antigen on the cancer cells. In multiclonal diseases, these therapies confer the development of antigen-less
clones, causing tumor escape and relapse. In this study, we developed nanoparticle-based bispeciﬁc T-cell engagers
(nanoBiTEs), which are liposomes decorated with anti-CD3 monoclonal antibodies (mAbs) targeting T cells, and mAbs
targeting the cancer antigen. We also developed a nanoparticle that targets multiple cancer antigens by conjugating multiple
mAbs against multiple cancer antigens for T-cell engagement (nanoMuTEs). NanoBiTEs and nanoMuTEs have a long half-life
of about 60 h, which enables once-a-week administration instead of continuous infusion, while maintaining efﬁcacy in vitro and
in vivo. NanoMuTEs targeting multiple cancer antigens showed greater efﬁcacy in myeloma cells in vitro and in vivo,
compared to nanoBiTEs targeting only one cancer antigen. Unlike nanoBiTEs, treatment with nanoMuTEs did not cause
downregulation (or loss) of a single antigen, and prevented the development of antigen-less tumor escape. Our nanoparticlebased immuno-engaging technology provides a solution for the major limitations of current immunotherapy technologies.

Introduction
Cancer immunotherapy improves the ability of the immune
system to recognize and combat cancer cells, which enables
long-term remission in cancer patients and is also in the
forefronts of cancer therapy [1, 2]. T-cell-based immunotherapies include chimeric antigen receptor T (CAR-T)
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cells and bispeciﬁc T-cell Engagers (BiTEs). CAR-T cells
are autologous T cells obtained from individual patients and
are genetically engineered to express an antibody singlechain variable fragment (scFv) to recognize and kill cancer
[3]. BiTEs are tandem scFv fragments connected by ﬂexible
linkers with one scFv targeting a T-cell speciﬁc molecule
such as CD3, while the other targets a tumor-associated
antigen, which allows the BiTEs to redirect the T cell to the
cancer cell, leading to T-cell-redirected activation and
tumor killing [4–7].
T-cell-based immunotherapy has shown promising clinical outcomes in many cancers including multiple myeloma
(MM) [4, 5] and Waldenstrom macroglobulinemia (WM)
[8]; however, these have signiﬁcant limitations. CAR-T
cells must be extracted from the patient, activated, expanded, genetically engineered, and puriﬁed ex vivo for reinjection into the patient [9, 10]. This process imposes
technical challenges and signiﬁcant expense. BiTEs, on the
other hand, have the advantage of being off the shelf for
immediate use in patients [11]; however, they have a poor
pharmacokinetic proﬁle, with a half-life of around 2 h [12],
imposing compromised patient quality of life, and increased
risk of infections related deaths [13–16]. Therefore, there is
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Fig. 1 Development of nanoparticle bispeciﬁc T-cell engagers
(nanoBiTEs). A Schematic of classic BiTEs, nanoparticle T-cell
engagers (nanoBiTEs), and the utilization of nanoBiTE to engage
T cells to cancer cells. B A scheme of the production of the nanoBiTE

using thin-ﬁlm evaporation method, followed by conjugation of mAbs
of choice such as anti-CD20 and anti-CD3. C The pharmacokinetic
proﬁle of nanoBiTEs with or without PEGgylation in vivo (n = 3;
means ± SD).

an urgent need to develop new forms of T-cell immunotherapies that overcome these limitations.

antibodies (mAbs) targeting T cells, and mAbs targeting the
cancer antigen (Fig. 1A). We hypothesized that the liposomal nature of nanoBiTEs will have a prolonged half-life.
We developed liposomes with or without stealth PEGylation conjugated to these anti-CD3 and anti-CD20 mAbs
(CD20/CD3 nanoBiTEs) (Fig. 1B). We chose to target
CD20 for targeting WM cells, since CD20 has been routinely and successfully used as a therapeutic target for WM

Results and discussion
We have developed nanoparticle-based BiTE (nanoBiTEs),
which are liposomes decorated with anti-CD3 monoclonal
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Fig. 2 Development of
nanoBiTEs for Waldenstrom
macroglobulinemia (WM). A
RMFI and percent of CD20
protein expression on the surface
of WM cells (n = 3; means ±
SD). B The effect of the number
of anti-CD20 mAbs conjugated
to the liposome on the binding
of the nanoBiTEs to
BCWM.1 cells, and the effect of
the number of anti-CD3 mAbs
conjugated to the liposome on
the binding of the nanoBiTEs to
T cells (n = 3; means ± SD). C
Binding of isotype/CD3 and
CD20/CD3 nanoBiTEs to WM
cells (n = 3; means ± SD). Twosided Student’s t test was used;
statistical signiﬁcance (p < 0.05)
between CD20/CD3 and
isotype/CD3 was indicated by
placing an asterisk.
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[17, 18]. Non-PEGylated nanoBiTEs improved the half-life
to about 36 h, while the PEGylated nanoBiTEs had even a
longer half-life of about 60 h (Fig. 1C). Therefore, we
adopted the PEGylated nanoBiTEs formulation for all
upcoming experiments. The longer half-life enabled
administration of the nanoBiTEs once a week as an intravenous (IV) bolus injection for in vivo experiments.
Clinically, the improved pharmacokinetic proﬁle will be
translated into a more convenient dosing regimen and
therefore a dramatic improvement in the patient’s quality of
life, and decrease risk of infections related to continuous
infusion. Other solutions that have been established to circumvent the low pharmacokinetic proﬁle include supplementing BiTEs with an Fc receptor or an antihuman serum
albumin binding construct [19, 20]; both methods prevent
the rapid elimination and degradation of BiTEs by the
neonatal Fc receptor [21, 22]. There are currently multiple
ongoing clinical trials testing these newly designed BiTEs
for efﬁcacy and toxicity [23–27].
First, we validated the use of CD20 as a target for the
treatment of WM. We measured the percent of WM cells
that express CD20. For both WM cell lines, CD20 is highly
expressed and on ~90% of cells (Fig. 2A). We then

MWCL.1

investigated the effect of the number of antibodies conjugated to the liposome. Increasing the number of antibodies conjugated to the liposomes did not increase the
binding of the nanoBiTEs to WM or T cells, which is
shown in Fig. 2B. Therefore, for all the upcoming experiments, we developed nanoBiTEs with one CD3 and one
CD20 mAb per liposome. We then tested the binding of the
CD20/CD3 nanoBiTEs to WM cells, compared to isotype
and CD3 conjugated nanoBiTEs (isotype/CD3). The CD20/
CD3 nanoBiTEs bound to the WM cells about 50-fold
greater than isotype/CD3 nanoBiTEs (Fig. 2C).
To demonstrate the therapeutic efﬁcacy of the nanoBiTEs,
we used our 3D tissue-engineered bone marrow (3DTEBM)
model [28] (Fig. 3A), in which we used primary BM aspirates
from patients to develop a 3D culture of the malignant BM
niche. The model is developed using all the cells in the tumor
microenvironment, not only tumor cells, but also other
accessory cells including T cells. We used the BM supernatant from patients to create the 3D matrix by cross-linking
ﬁbrinogen naturally found in the marrow; the cellular fraction
is also reintroduced into the scaffold. The 3DTEBM recapitulates cellular structures and oxygen gradients of the BM
niche, and allows proliferation of primary cells from various
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Fig. 3 WM killing and T-cell
activation with nanoBiTEs
in vitro. A A scheme of
3DTEBM cultures used to
determine the effect of
nanoBiTEs on T-cell activation
and cancer cell killing in vitro.
B The effect of isotype/CD3 and
CD20/CD3 nanoBiTEs on the
killing of WM cells with T cells
(n = 4; means ± SD). C The
effect of isotype/CD3 and
CD20/CD3 nanoBiTEs on the
expression of CD69 on CD4+
and CD8+ T cells as a marker of
T-cell activation (n = 3; means
± SD). Two-sided Student’s
t test was used; statistical
signiﬁcance (p < 0.05) between
CD20/CD3 and isotype/CD3
was indicated by placing an
asterisk.
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Fig. 4 WM killing and T-cell
activation with nanoBiTEs
in vitro. A Quantitative and
B qualitative analysis of the
effect of isotype/CD3 and
CD20/CD3 nanoBiTEs on the
progression of WM tumors
in vivo (n = 7; means ± SEM).
C The effect of isotype/CD3 and
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survival of WM-bearing mice
(n = 3). Log-rank test was used
to compare the Kaplan–Meier
curves; statistical signiﬁcance
(p < 0.05) between CD20/CD3
and isotype/CD3 was indicated
by placing an asterisk.
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expressions on primary MM
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mRNA gene expressions of
BCMA, CS1, and CD38 in a
cohort of 600 MM patients (n =
600). B RMFI and C percent
protein expression of BCMA,
CS1, and CD38 on MM cell
lines and three patient primary
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hematologic malignancies (such as WM and MM). It can be
also used with cell lines in combination with the tumor
microenvironment (without cancer cells) isolated from
patients. We suggest this model as an optimal model for
testing the effect of T-cell-based immunotherapies in vitro.
We tested the effect of CD20/CD3 nanoBiTEs on the
survival of WM cells in the 3DTEBM. CD20/CD3 nanoBiTEs induced 60–70% killing of WM cells, while the
isotype/CD3 nanoBiTEs did not induce any killing whatsoever (Fig. 3B). We ensured that the MM cell lysis seen
with nanoBiTEs was T cell mediated by incubating WM
cells and nanoBiTEs or isotype/CD3 without T cells and
observed no killing of WM cells as seen in Supplementary
Fig. 1. In addition, we tested the activation of T cells by
nanoBiTEs in the 3DTEBM. CD69 expression, as a marker
of T-cell activation, in CD4 and CD8 T cells (Fig. 3C) was
higher after treatment with CD20/CD3 nanoBiTE compared
to isotype/CD3. Moreover, the CD8 T cells showed higher
activation compared to CD4 T cells. Secretion of cytokines
is a hallmark of T-cell activation. Supplementary Fig. 2
shows the cytokine secretion of T cells following their
activation with CD20/CD3 and isotype/CD3 nanoBiTEs in
the 3DTEBM. The presence of IL-2, IL-6, IL-10, TNF-α,
and IFN-γ is signiﬁcantly greater when treated with CD20/
CD3 compared to isotype/CD3. These results indicate that
the CD20/CD3 nanoBiTEs are speciﬁc to WM cells and that
the effect is only mediated via T-cell engagement.

CS1

CD38

BCMA

Protein expression (%)

BCMA
Protein expression (RMFI)

30000

CS1

CD38

100
80
60
40

20
0

To demonstrate the therapeutic efﬁcacy in vivo, we chose
an aggressive xenograft WM model by injecting
BCWM.1 cells IV (with humanized T cells), which kills the
mice in less than 3 weeks following injection, if not treated,
this represents the clinically aggressive/relapsed form of the
disease. Mice treated with isotype/CD3 nanoBiTEs showed
fast tumor progression and death of the entire cohort within
21 days. In contrast, mice treated with WM-targeting CD20/
CD3 nanoBiTE showed slower tumor progression at days 14
and 21, a signiﬁcant reduction at day 28 (compared to day
21), and complete eradication of the tumor by day 35
(Fig. 4A, B). The entire cohort survived with no signs of
disease for as long as 2 months, which is when the experiment
was stopped (Fig. 4C). These results demonstrate that the
CD20/CD3 nanoBiTE immunotherapy has an outstanding
potential to treat/cure even the most aggressive forms of WM.
The second major limitation of BiTEs (and CAR-T cells)
is that they are designed to target only one antigen on cancer
cells. Preclinical studies have demonstrated that targeting
multiple antigens by CAR-T cells or BiTEs are still technically challenging [29–33]. Especially in a multiclonal
disease like MM [34–37], these therapies confer the
development antigen-less clones, causing tumor escape and
relapse of the disease [4, 5].
Several antigens were used previously as targets for Tcell-based immunotherapy in MM, including B-cell
maturation antigen (BCMA), CD38, and SLAMF7 (CS1)
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[38–42]. Gene expression analysis of these antigens in MM
patients showed that the expression of each marker was
highly variable, emphasizing the heterogeneity of the
expression of these genes in MM patients (Fig. 5A). We
also tested the surface protein expression of these antigens
on MM cells, which further showed and emphasized the
variability and presence of expression (Fig. 5B, C). Such
heterogeneous expression presents a challenge for the efﬁcacy of any immunotherapy that targets any of these antigens as a single target.
Therefore, we developed a nanoparticle that targets
multiple cancer antigens simultaneously by conjugating
multiple mAbs against multiple cancer antigens for T-cell
engagement (nanoMuTEs; Fig. 6A). We hypothesized that
nanoMuTEs will target multiple clones simultaneously,
prevent antigen-less tumor escape, and be more efﬁcacious
than targeting individual antigens.

MM.1S

RPMI-8226

Patient 1

Patient 2

Patient 3

We tested the binding of three different BCMA/CD3,
CS1/CD3, and CD38/CD3 nanoBiTEs (each targeting one
antigen) and BCMA/CS1/CD38/CD3 nanoMuTEs (targeting all three antigens) to MM cells. Each nanoBiTE bound
to MM cells more than the isotype/CD3 nanoBiTE, in
correlation with the surface expression of each antigen;
nanoMuTEs showed higher binding compared to each
nanoBiTE alone (Fig. 6B).
We further tested T-cell-induced killing of MM cells by
nanoBiTEs and nanoMuTEs in the 3DTEBM. Each nanoBiTEs induced more MM killing compared to isotype/CD3,
while nanoMuTEs induced more MM killing compared to
each nanoBiTE (Fig. 6C). We also tested T-cell activation.
Activation of CD4 and CD8 T cells (Supplementary
Fig. 3Ai, ii, respectively) was higher after treatment with
each nanoBiTE compared to isotype/CD3, while activation
after treatment with nanoMuTEs was higher than each
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Fig. 7 Circumventing antigen-less tumor escape with nanoMuTEs in vitro. A Schematic of the mechanism of tumor escape after
treatment with immunotherapies targeting one antigen due to development of antigen-less tumor clones which cause relapse of the disease. B The effect of nanoBiTEs and nanoMuTEs on the expression of
BCMA, CS1, and CD38 on MM cells remaining following treatment
(n = 4; means ± SD). C The effect of blocking tumor antigens

(BCMA, CS1, and CD38) on the binding of nanoBiTEs and nanoMuTEs to MM cells (n = 3; means ± SD). One-way and two-way
ANOVA was used; statistical signiﬁcance (p < 0.05) was indicated
using an asterisk symbol (*) which represents signiﬁcance between the
nanoBiTE and isotype/CD3 in panel B and represents signiﬁcance
between the nanoBiTE with no blocking and nanoBiTE with blocking
in panel C.

nanoBiTE. CD8 T cells showed higher activation compared
to CD4 T cells when treated with any of the nanoBiTEs or
nanoMuTEs. In addition, we investigated the presence of
cytokines following treatment with nanoBiTEs or nanoMuTEs (Supplementary Fig. 3Bi, ii). The presence of IL-2,
IL-6, IL-10, TNF-α, and IFN-γ is signiﬁcantly greater when
treated with each nanoBiTE compared to isotype/CD3;
nanoMuTEs induced greater secretion than the nanoBiTEs.
Next, we developed antigen-less clones by testing the
effect of nanoBiTEs and nanoMuTEs on the expression of
antigens on MM cells (Fig. 7A). When treated with
BCMA/CD3, CS1/CD3, or CD38/CD3, the expression of
BCMA, CS1, and CD38 in the whole MM cell population
was decreased, respectively (Fig. 7B), but not affected by
the nanoBiTEs with other targets. The decrease can be
attributed to killing of the population with high expression
of the speciﬁc antigen or downregulation of the speciﬁc
antigen on the cells, both of which contribute to the
development of antigen-less populations. In contrast, the
treatment with nanoMuTEs did not generate a population
with lower expression of any of the three antigens, which
suggests that treatment with nanoMuTEs will not cause
antigen-less tumor escape and create a better therapeutic
strategy.

We next investigated the effect of blocking (as a model
for downregulation) of BCMA, CD38, and CS1 on the
binding of nanoBiTEs and nanoMuTE to MM cells. The
binding of each of the nanoBiTEs was reduced when the
antigens on the cells were blocked with the respective
blocking antibody against the antigen that it is targeting. In
contrast, no signiﬁcant decrease of the binding of nanoMuTEs was observed when treated with any of the antibodies blocking alone, likely because the binding was
facilitated through other antigens. Binding of nanoMuTEs
was decreased when treated with a combination of the three
blocking antibodies (Fig. 7C). This demonstrates that
downregulation (or loss) of an antigen will reduce the
binding (and hence the efﬁcacy) of the nanoBiTE, as
observed clinically with the treatment with CAR-T cells and
BiTEs, but did not affect the binding of nanoMuTEs, which
creates a better therapeutic strategy.
We also investigated the biodistribution of nanoBiTEs/
nanoMuTEs and T cells following 24 h (Supplementary
Fig. 4 and Fig. 8A, respectively). We see speciﬁc accumulation of nanoBiTEs and nanoMuTEs at the tumor site
(BM) compared to isotype/CD3. Consequently, T cells were
speciﬁcally engaged to the tumor site following treatment
with nanoBiTEs or nanoMuTEs compared to isotype/CD3.
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Fig. 8 Circumventing antigenless tumor escape with
nanoMuTEs in vivo. A
Biodistribution of T cells
following 24 h in vivo (n = 3;
means ± SD). B The effect of
nanoBiTEs and nanoMuTEs on
the progression of MM tumors
in vivo (n = 7; means ± SEM).
C The effect of nanoBiTEs and
nanoMuTEs on the survival of
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2353

*

80
60

*#
*#
*#

40
20
0
0

10

Next, the pharmacokinetic proﬁle of each of the nanoBiTEs
and nanoMuTEs was similar to the CD20/CD3 nanoBiTEs
with a half-life of ~50–60 h (Supplementary Fig. 5). To
demonstrate the therapeutic efﬁcacy of the nanoBiTEs and
nanoMuTEs in vivo, we used an aggressive xenograft MM
model by injecting MM.1S IV (with humanized T cells),
which kills the mice in less than 4–5 weeks after injection, if
not treated, and represents the clinically aggressive/relapsed
form of the disease. Treatment with isotype/CD3 nanoBiTEs showed fast tumor progression and death of the
cohort within 40 days (Fig. 8B and Supplementary Fig. 6).
Treatment of each of the nanoBiTEs targeting one antigen
(BCMA, CS1, or CD38) resulted in delayed tumor progression and prolonged survival, while the treatment with
the nanoMuTEs induced longer tumor progression delay
and resulted in survival of the entire cohort till 55 days
(Fig. 8C).
Our study successfully shows the proof-of-concept of
redirecting T cells to cancer using nanoparticles. The
nanoBiTEs/nanoMuTEs used for WM and MM were able to
induce T-cell-mediated cancer cell killing. The effect of the
CD20/CD3 nanoBiTEs for the treatment of WM was signiﬁcantly more profound than the nanoBiTEs/nanoMuTEs
used for MM; CD20/CD3 cured the WM xenograft murine
model, whereas the nanoBiTEs/nanoMuTEs prolonged
survival of MM mice by only 10–20 days. This is, likely,
due to the difference in antigen level and presence on each
cancer type; expression of CD20 was prevalent in the vast

20

30
Days

40

50

majority of WM cells, while the expression of BCMA, CS1,
and CD38 was variable on MM. Moreover, the intensity of
the expression of CD20 on WM cells was 2–3 orders of
magnitude higher than BCMA, CS1, and CD38 on MM.
In conclusion, the nanoBiTE/nanoMuTE platform uses
nanotechnology to provide a relatively easy-to-make and
off-the-shelf solution to circumvent the major limitations of
the current immunotherapy technologies (CAR-T cells and
BiTEs). It takes advantage of the established high speciﬁcity of mAbs to better navigate the robust immune response
to eliminate cancer. In this instance, it would be easy to
modify this system to generate a new nanoBITE as an
immunotherapy to target any cancer type by using existing
or new mAbs that have the ability to speciﬁcally bind to the
cancer cells of interest. The ﬂexibility of the nanoparticlebased immuno-engaging technology provides a general
platform with groundbreaking translational potential for
developing easy-to-make, speciﬁc, and efﬁcacious immunotherapy for cancer in general.

Methods
Materials and reagents
All biotinylated and ﬂuorescent antibodies, human CD138
microbeads, and Pan T Cell Isolation Kits were purchased
from Miltenyi Biotec (Bergisch Gladbach, Germany).

2354

DMEM, RPMI-1640, L-glutamine, penicillin–streptomycin,
and phosphate buffered saline (PBS) were purchased from
Corning (Corning, NY). Fetal bovine serum, live-cell dyes,
lipophilic tracers, collagenase, and counting beads were
purchased from Life Technologies (Carlsbad, CA). 1,2dipalmitoyl-sn- glycero-3-phosphocholine (DPPC), 1,2distearoyl-sn-glycero-3-phosphoethanolamine-N- [amino
(polyethylene glycol)-2000] (DSPE-PEG2000), and polycarbonate membranes were purchased from Avanti Polar
Lipids (Alabaster, AL). Cholesterol and chloroform were
purchased from Millipore Sigma (Burlington, MA). Streptavidin conjugation kit was purchased from Abcam (Cambridge, UK). Human Cytokine Array Q1 was purchased
from RayBiotech (Peachtree Corners, GA). All mice used in
this study were NCG (strain: 572), female, 50–56 days old,
and purchased from Charles River (Wilmington, MA). All
mice experiments in this study were in compliance with the
Institutional Animal Care and Use Committee at
Washington University.

Cells
H929, MM.1S, and RPMI-8226 were purchased and
authenticated by American Type Culture Collection (Manassas, Virginia). All cell lines were tested for mycoplasma
contamination. BCWM.1 and MWCL.1 were a gift from
Irene Ghobrial. Primary BM samples were isolated from
MM patients at Washington University School of Medicine
(IRB # 201102270) and subsequently selected for MM cells
with the use of CD138 human microbeads. Informed consent was obtained from all individuals in accordance with
the Declaration of Helsinki. Normal donor peripheral blood
mononuclear cells (PBMCs) were isolated from healthy
donors using Ficoll centrifugation [43] and subsequently
separated for T cells using a human Pan T Cell Isolation Kit
(Miltenyi Biotec). Hs505.T cells were cultured in DMEM
with 4.5 g/l glucose and L-glutamine with the addition of
addition of 10% fetal bovine serum and 1%
penicillin–streptomycin. The other cell lines were cultured
in RPMI-1640 with the addition of 10% fetal bovine serum,
2 mM of L-glutamine, and 1% penicillin–streptomycin.

Preparation and characterization of the nanoBiTEs
and nanoMuTEs
As described in Fig. 1B, nanoBiTEs consisted of three
components: cholesterol, DPPC, and DSPE-PEG2000 with
a mass ratio equivalent to 30:65:5, respectively. Lipids were
mixed and solubilized in chloroform, and evaporated to
form a thin ﬁlm [44, 45]. Then, the ﬁlm was hydrated with
PBS, and the resulting suspension was extruded using the
Avestin LiposoFast LF-50 (Ottawa, ON, Canada) with 100
nm polycarbonate membranes to yield unilamellar
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liposomes. Streptavidin was conjugated to the amine groups
on the surface of the liposomes according to the protocol of
the manufacturer (Abcam), to activate the liposomes. Biotinylated antibodies were added to bind to the streptavidin
for targeting, as previously described [46]. For detailed
amounts of each reagent used, please see Supplementary
Table 1. Malvern Zetasizer Nano ZS90 (Malvern, Worcestershire, UK) was used to determine zeta-potential, diameter, and polydispersity index of the each preparation (see
Supplementary Table 2 for details).

Pharmacokinetics of nanoBiTEs and nanoMuTEs
Each nanoBiTE or nanoMuTE was stained with a ﬂuorescent tracer (DiD and injected IV injection to NSG mice at
.5 mg/mouse (n = 3 for each formulation). Blood (50 μl)
was taken from the tail vein of each mouse before treatment,
and 0.25, 6, 24, 48, 72, and 96 h after treatment. Fluorescence of whole blood or plasma was measured at 644/665
nm using a SpectraMax i3 plate reader (Molecular Devices,
San Jose, CA). Half-life was calculated using polynomial
regression.

Cell surface protein expression analysis
Cell lines or primary CD138+ MM cells were incubated
with APC-anti-CD20, APC-anti-BCMA, APC-anti-CS1, or
APC-anti-CD38 antibodies in 4 °C for 1 h; then washed,
spun down, resuspended in 100 μl and analyzed by ﬂow
cytometry using MACSQuant Analyzer 10 with Ex = 635
nm and Em = 655–730 nm [47]. Cells were gated using
FSC and SSC, and analyzed for relative mean ﬂuorescent
intensity (RMFI) of APC using BD FlowJo Software [48].

Liposome binding and binding following antigen
loss in vitro
Each nanoBiTE or nanoMuTE was stained with a ﬂuorescent tracer DiO. Cell lines and primary cells (30,000 cells
in 100 μl for each data point) were treated with or without
isotype/CD3, nanoBiTEs, or nanoMuTEs (3.7 nM) for 2 h
at 37 °C. In some cases (for mimicking antigen downregulation), cells were treated with 33.3 nM of anti-BCMA,
CS1, and/or CD38 antibody of the same clone for 1 h prior
to the 2-h treatment with nanoBiTEs or nanoMuTEs. Following the 2-h treatment with nanoBiTEs or nanoMuTEs,
the cells were stained with anti-BCMA, CS1, or CD38 of a
different clone for 1 h. Then, cells were spun down, washed
with PBS, resuspended in 100 μl and analyzed by ﬂow
cytometry using MACSQuant Analyzer 10 with Ex = 488
nm and Em = 525/50 nm. Cells were gated using forward
and side scatter, and analyzed for MFI of DiO using BD
FlowJo Software.
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3DTEBM culture system
The culture’s cellular content can be customized by inclusion of various cell populations. For testing patient samples,
BM mononuclear cells were used as a whole, including the
primary cancer cells and T cells. 3DTEBM was established
by cross-linking ﬁbrinogen in patient BM supernatant using
CaCl2, as previously described [28]. Brieﬂy, for testing cell
lines, 30,000 cancer cells were combined with 30,000
T cells; for primary cells 100,000 BM mononuclear cells
were used as whole. Cells were suspended in BM supernatant which was then cross-linked with CaCl2 to form the
3D matrix. The 3DTEBM was supplemented with media on
top and incubated at 37 °C for 4 days. At time of analysis,
the scaffolds were digested with collagenase (Gibco, Life
Technologies) for 2 h at 37 °C; cells were retrieved, washed,
and subjected to ﬂow cytometry analysis.
For the development of antigen-less populations, the
above procedure was followed and the remaining cells were
incubated with APC-anti-BCMA, APC-anti-CS1, or APCanti-CD38 antibodies in 4 °C for 1 h; then washed, spun
down, resuspended in 100 μl and analyzed by ﬂow cytometry using MACSQuant Analyzer 10 with Ex = 635 nm
and Em = 655–730 nm. Cells were gated using FSC and
SSC, and analyzed for MFI of APC using BD FlowJo
Software.

Cell survival
Cell lines (prelabeled with ﬂuorescent tracer DiO) and primary cells were incubated with T cells in 3DTEBM and
treated with or without isotype/CD3, nanoBiTEs, or nanoMuTEs at a concentration of 3.7 nM for 4 days. Before
digestion of the matrix, 5 μl of counting beads (Miltenyi
Biotec) were added to the culture. The matrix was then
digested, cells were retrieved, and analyzed by ﬂow cytometry using MACSQuant Analyzer 10. For cell lines, the
number of tumor cells analyzed as DiO+ cells and normalized to the number of counting beads using BD FlowJo
Software. For primary cells, MM cells were identiﬁed as
CD38+/CD3−/CD14−/CD16−/CD19−/CD123−, as previously described [49], and the number of MM primary
cells was normalized to the number of counting beads using
BD FlowJo Software. For the analysis of WM killing
without T cells, the above procedure was mimicked except
without including T cells in 3DTEBM.

Activation of T cells
Cells were in 3DTEBM and treated with or without isotype/
CD3, nanoBiTEs, or nanoMuTEs at a concentration of 3.7
nM for 4 days. Then, cultures were digested, and the cells
were retrieved and incubated with PE anti-CD3, FITC anti-
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CD4, Violet anti-CD8, and APC-anti-CD69 antibodies for
1 h in 4 °C, washed with PBS, spun down, and suspended in
PBS again. These samples were analyzed by ﬂow cytometer
using MACSQuant Analyzer 10 with Ex = 488, 488, 405,
and 635 nm and Em = 585/40, 525/50, 450/50, 655–730 nm,
respectively. Cells were gated using FSC and SSC followed
by double positive CD3+/CD4+ or CD3+/CD8+, both of
which were analyzed for % of cells positive for CD69 using
BD FlowJo Software.
For cytokine secretion, the supernatant was kept and the
3DTEBM was digested for 2 h using collagenase following
the 4-day incubation period. Once the 3DTEBM was
digested and samples were spun down, the supernatant
(with collagenase) was then added to the supernatant collected earlier. Subsequently, the samples were analyzed for
cytokine presence following the manufacturer’s protocol
and scanned using the InnoScan 710 microarray ﬂuorescence scanner (Innopsys) by the manufacturer of the
cytokine array.

NanoBiTE/nanoMuTE and T-cell biodistribution,
tumor efﬁcacy, and survival in vivo
For all animal studies, mice were randomized into groups
and no blinding was done in this study. For biodistribution,
human MM.1S-CBR cells (2 × 106/mouse) were injected IV
to NSG mice to generate the MM tumor models. PBMCs
were isolated from healthy human donors using Ficoll
centrifugation and subsequently separated for T cells using
a human Pan T Cell Isolation Kit (Miltenyi Biotec), as
previously described [43]. T cells (5 × 106/mouse) were
stained with calcein violet and injected IV to each mouse
3 weeks following propagation of the MM cells. One hour
post T-cell injection, mice were treated IV with isotype/
CD3, nanoBiTEs, or nanoMuTEs stained with DiD (0.5 mg/
mouse). Organs were extracted 24 h later and analyzed via
ﬂow cytometry.
For tumor efﬁcacy and survival, human BCWM.1 or
MM.1S luciferase cells (2 × 106/mouse) were injected IV to
NSG mice to generate the WM or MM tumor models,
respectively [50]. T cells (5 × 106/mouse) were injected IV
to each mouse 7 days after the injection of tumor cells. One
hour post T-cell injection, mice were treated IV with isotype/CD3, nanoBiTEs, or nanoMuTEs (0.5 mg/mouse) and
weekly thereafter.
For tumor progression, mice were imaged weekly using
bioluminescent imaging. Mice were injected with Dluciferin (150 μg/kg) intraperitoneally, and tumor burden
was detected using an IVIS 50 bioluminescence imaging
system (PerkinElmer, Waltham, MA) 10 min post luciferin
injection, and images were analyzed using Living Image
2.6 software (PerkinElmer). For survival, mice were monitored on a daily basis to record survival.
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Gene expression analysis
Gene expression data on MM patients were extracted from
the previously published literature [51] describing data from
600 newly diagnosed MM patients, in which plasma cells
were subsequently selected using anti-CD138 beads and
mRNA gene expression was performed using the Affymetrix U133 Plus 2.0 microarray platform (Santa Clara, CA)
and analyzed using the Affymetrix Microarray Suite
GCOS1.1. BCMA, CS1, and CD38 gene expression was
analyzed and plotted using Python.

Statistical analyses
All in vitro experiments in this study was independently
replicated three times. Sample size for laboratory animals
was estimated using published guidelines [52]. In vitro
experiments were performed in quadruplicates, and in vivo
experiments consisted of seven mice each; data from
in vitro and in vivo experiments were expressed as means ±
standard deviation. Data normality was analyzed using
residuals, and variance similarity across groups was also
analyzed by examining the expected variance of each group.
Statistical signiﬁcance was analyzed using a Student’s t test
and one-way or two-way analysis of variance (ANOVA).
Log-rank test was used to compare the Kaplan–Meier
curves. P values less than 0.05 were used to indicate statistically signiﬁcant differences.

Data availability
All data generated are available upon request.
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